{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:28:44Z","timestamp":1780756124587,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["16K08902"],"award-info":[{"award-number":["16K08902"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006062","name":"Foundation for Promotion of Cancer Research","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10637-020-01023-z","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T20:02:46Z","timestamp":1603483366000},"page":"595-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-7827","authenticated-orcid":false,"given":"Masahide","family":"Fukudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Azumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272\u20137283","journal-title":"Clin Cancer Res"},{"key":"1023_CR2","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931\u20131939","journal-title":"Lancet"},{"key":"1023_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127","journal-title":"N Engl J Med"},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115","journal-title":"N Engl J Med"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","volume":"52","author":"Y Chen","year":"2013","unstructured":"Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK (2013) Clinical pharmacology of axitinib. Clin Pharmacokinet 52:713\u2013725","journal-title":"Clin Pharmacokinet"},{"key":"1023_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/dmd.115.065615","volume":"44","author":"MA Zientek","year":"2016","unstructured":"Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D, Smith BJ (2016) In vitro kinetic characterization of axitinib metabolism. Drug Metab Dispos 44:102\u2013114","journal-title":"Drug Metab Dispos"},{"key":"1023_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1124\/dmd.113.056531","volume":"42","author":"BJ Smith","year":"2014","unstructured":"Smith BJ, Pithavala Y, Bu HZ, Kang P, Hee B, Deese AJ, Pool WF, Klamerus KJ, Wu EY, Dalvie DK (2014) Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug Metab Dispos 42:918\u2013931","journal-title":"Drug Metab Dispos"},{"key":"1023_CR8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/bcp.12206","volume":"77","author":"M Garrett","year":"2014","unstructured":"Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA (2014) Population pharmacokinetic analysis of axitinib in healthy volunteers. Br J Clin Pharmacol 77:480\u2013492","journal-title":"Br J Clin Pharmacol"},{"key":"1023_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcph.73","volume":"53","author":"BI Rini","year":"2013","unstructured":"Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ (2013) Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53:491\u2013504","journal-title":"J Clin Pharmacol"},{"key":"1023_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","volume":"14","author":"BI Rini","year":"2013","unstructured":"Rini BI, Melichar B, Ueda T, Gr\u00fcnwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E (2013) Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14:1233\u20131242","journal-title":"Lancet Oncol"},{"key":"1023_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.clgc.2016.04.005","volume":"14","author":"BI Rini","year":"2016","unstructured":"Rini BI, Tomita Y, Melichar B, Ueda T, Gr\u00fcnwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E (2016) Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. Clin Genitourin Cancer 14:499\u2013503","journal-title":"Clin Genitourin Cancer"},{"key":"1023_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00280-014-2606-6","volume":"74","author":"MA Tortorici","year":"2014","unstructured":"Tortorici MA, Cohen EE, Pithavala YK et al (2014) Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol 74:1279\u20131289","journal-title":"Cancer Chemother Pharmacol"},{"key":"1023_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clgc.2012.12.004","volume":"11","author":"BI Rini","year":"2013","unstructured":"Rini BI, de La Motte RT, Harzstark AL et al (2013) Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer 11:107\u2013114","journal-title":"Clin Genitourin Cancer"},{"key":"1023_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","volume":"26","author":"BI Rini","year":"2015","unstructured":"Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Gr\u00fcnwald V (2015) Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 26:1372\u20131377","journal-title":"Ann Oncol"},{"key":"1023_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1349-7006.2009.01465.x","volume":"101","author":"T Mukohara","year":"2010","unstructured":"Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H (2010) Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101:963\u2013968","journal-title":"Cancer Sci"},{"key":"1023_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1124\/dmd.110.037317","volume":"39","author":"B Poller","year":"2011","unstructured":"Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2011) Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos 39:729\u2013735","journal-title":"Drug Metab Dispos"},{"key":"1023_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00228-011-1171-8","volume":"68","author":"M Brennan","year":"2012","unstructured":"Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC (2012) Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 68:645\u2013655","journal-title":"Eur J Clin Pharmacol"},{"key":"1023_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"1023_CR19","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","volume":"23","author":"HS Rugo","year":"2005","unstructured":"Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474\u20135483","journal-title":"J Clin Oncol"},{"key":"1023_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2131\/jts.38.349","volume":"38","author":"M Okubo","year":"2013","unstructured":"Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H (2013) The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 38:349\u2013354","journal-title":"J Toxicol Sci"},{"key":"1023_CR21","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","volume":"123","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E (2020) Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. Br J Cancer 123:898\u2013904","journal-title":"Br J Cancer"},{"key":"1023_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.clgc.2015.07.001","volume":"13","author":"BI Rini","year":"2015","unstructured":"Rini BI, Escudier B, Hariharan S, Roberts WG, Tarazi J, Rosbrook B, Askerova Z, DeAnnuntis LL, Motzer RJ (2015) Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 13:540\u2013547","journal-title":"Clin Genitourin Cancer"},{"key":"1023_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(19)30513-3","volume":"20","author":"MC Ornstein","year":"2019","unstructured":"Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI (2019) Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol 20:1386\u20131394","journal-title":"Lancet Oncol"},{"key":"1023_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102:765\u2013776","journal-title":"Clin Pharmacol Ther"},{"key":"1023_CR25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/0284186X.2017.1311024","volume":"56","author":"FJE Lubberman","year":"2017","unstructured":"Lubberman FJE, van Erp NP, Ter Heine R et al (2017) Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. Acta Oncol 56:1238\u20131240","journal-title":"Acta Oncol"},{"key":"1023_CR26","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s10637-019-00743-1","volume":"37","author":"G Beinse","year":"2019","unstructured":"Beinse G, Hulin A, Rousseau B (2019) Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma. Investig New Drugs 37:1289\u20131291","journal-title":"Investig New Drugs"},{"key":"1023_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12032-018-1113-8","volume":"35","author":"R Igarashi","year":"2018","unstructured":"Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T (2018) Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Med Oncol 35:51","journal-title":"Med Oncol"},{"key":"1023_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/jcph.1521","volume":"60","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Otori T, Inoue R, Yano S, Hirata H, Matsumoto H, Matsuyama K, Matsuyama H (2020) Pharmacokinetics of neoadjuvant axitinib influenced the efficacy in patients with advanced renal cell carcinoma. J Clin Pharmacol 60:256\u2013263","journal-title":"J Clin Pharmacol"},{"key":"1023_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40262-014-0207-5","volume":"54","author":"Y Chen","year":"2015","unstructured":"Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK (2015) Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma. Clin Pharmacokinet 54:397\u2013407","journal-title":"Clin Pharmacokinet"},{"key":"1023_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/cts.12626","volume":"12","author":"RN Schuck","year":"2019","unstructured":"Schuck RN, Pacanowski M, Kim S, Madabushi R, Zineh I (2019) Use of titration as a therapeutic individualization strategy: an analysis of food and drug administration-approved drugs. Clin Transl Sci 12:236\u2013239","journal-title":"Clin Transl Sci"},{"key":"1023_CR31","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 152:104609","journal-title":"Pharmacol Res"},{"key":"1023_CR32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED (2016) Venetoclax: first global approval. Drugs 76:979\u2013987","journal-title":"Drugs"},{"key":"1023_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Brigatinib: first global approval. Drugs 77:1131\u20131135","journal-title":"Drugs"},{"key":"1023_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","volume":"20","author":"TS Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A (2019) Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 20:1070\u20131082","journal-title":"Lancet Oncol"},{"key":"1023_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jjco\/hyw103","volume":"46","author":"Y Tomita","year":"2016","unstructured":"Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, Naito S, Akaza H (2016) Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol 46:1031\u20131041","journal-title":"Jpn J Clin Oncol"},{"key":"1023_CR36","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1111\/cas.14449","volume":"111","author":"T Osawa","year":"2020","unstructured":"Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N, the Japanese Urological Oncology Group (2020) Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Cancer Sci 111:2460\u20132471","journal-title":"Cancer Sci"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01023-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01023-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01023-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:58:53Z","timestamp":1678510733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01023-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01023-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"4 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this study was approved by the institutional ethics committee of Asahikawa Medical University (#15018). The study was performed in accordance with the Declaration of Helsinki and its amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}